Pulmatrix, Inc.

What they do

Pulmatrix historically developed inhaled dry powder therapeutics using its patented iSPERSE technology for migraine and respiratory diseases. Its pipeline includes PUR1900 (inhaled itraconazole for fungal infections) and PUR3100 (inhaled DHE for acute migraine). The company is now focused on completing a merger with Eos SENOLYTIX, a privately held biotech developing gerotherapeutic peptides for aging-related diseases using the MitoXcel platform.

Revenue drivers

• PUR1900 royalties from Cipla — Pulmatrix receives 2% royalties on future net sales of PUR1900 by Cipla outside the U.S. if commercialized; U.S. rights are shared 50/50 with Cipla. No product is yet marketed.
• iSPERSE technology licensing — The iSPERSE technology is licensed to MannKind Corporation and Cipla Technologies for certain fields of use, but the filing does not specify current revenue contributions.
• Legacy collaboration revenue — Revenue has historically come from collaborations and grants; annual revenue was $7.8M in 2024 and $7.3M in 2023, with no recent quarterly revenue reported in the latest 8-K.

Recent performance

For fiscal year 2025, revenue was not disclosed in the excerpts, but net loss improved to $-5.2M from $-9.6M in 2024. Operating cash flow also improved to $-5.4M in 2025 from $-10.7M in 2024. As of June 30, 2026, cash and equivalents were $2.2M, total assets were $3.2M, and shareholder equity was $2.6M.

Strategy

Pulmatrix is seeking to complete the proposed merger with Eos SENOLYTIX, which is expected to close in Q3 2026. In connection with the merger, the company raised $1.0M gross proceeds from a private placement of Series B Convertible Preferred Stock to an Eos affiliate. Management also stated it is seeking to out-license or monetize its clinical assets, including PUR1900 and PUR3100, while the merger advances.

Risks

• Going concern risk — The company has a history of recurring losses and negative operating cash flows and lacks sufficient liquidity to continue operations without additional financing or the successful merger.
• Merger completion risk — The merger with Eos is subject to customary closing conditions, including stockholder approval, and may not be completed on the anticipated timeline or at all.
• Dependence on partners — Future revenue from PUR1900 depends on Cipla's successful Phase 3 trial and commercialization, which is outside Pulmatrix's control.
• Nasdaq compliance risk — The company may fail to maintain compliance with Nasdaq's listing standards, which could lead to delisting and adversely affect liquidity.

Outlook

Management anticipates the merger with Eos to close in the third quarter of 2026, subject to closing conditions. A Form S-4 has been filed and amended to support the transaction. If the merger closes, Eos's business will become the combined company's focus. Additionally, Pulmatrix expects Cipla to commence a Phase 3 trial for PUR1900 in 2026 outside the U.S.